The PRMT6/PARP1/CRL4B Complex Regulates the Circadian Clock and Promotes Breast Tumorigenesis
Advanced Science · 2023
DOI: 10.1002/advs.202202737 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Tianshu Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Cancer and Microbiome, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Can…. Hauptthemen laut MEDLINE: Circadian Clocks, Breast Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Major State Basic Research Development Program of China, Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Circadian rhythms, as physiological systems with self‐regulatory functions in living organisms, are controlled by core clock genes and are involved in tumor development. The protein arginine methyltransferase 6 (PRMT6) serves as an oncogene in a myriad of solid tumors, including breast cancer. Hence, the primary aim of the current study is to investigate the molecular mechanisms by which the PRMT6 complex promotes breast cancer progression. The results show that PRMT6, poly(ADP‐ribose) polymerase 1 (PARP1), and the cullin 4 B (CUL4B)‐Ring E3 ligase (CRL4B) complex interact to form a transcription‐repressive complex that co‐occupies the core clock gene PER3 promoter. Moreover, genome‐wide analysis of PRMT6/PARP1/CUL4B targets identifies a cohort of genes that is principally involved in circadian rhythms. This transcriptional‐repression complex promotes the proliferation and metastasis of breast cancer by interfering with circadian rhythm oscillation. Meanwhile, the PARP1 inhibitor Olaparib enhances clock gene expression, thus, reducing breast carcinogenesis, indicating that PARP1 inhibitors have potential antitumor effects in high‐PRMT6 expression breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Cancer and Microbiome, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Un…
- Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China.
- Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China.
ORCID-Profile: Yan Wang
Förderung
- National Natural Science Foundation of China
- Major State Basic Research Development Program of China
- Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
Zitieren
APA
Yang, T., Huang, W., Ma, T., Yin, X., Zhang, J., Huo, M., Hu, T., Gao, T., Liu, W., Zhang, D., Yu, H., Teng, X., Zhang, M., Qin, H., Yang, Y., Yuan, B., & Wang, Y. (2023). The PRMT6/PARP1/CRL4B Complex Regulates the Circadian Clock and Promotes Breast Tumorigenesis. Advanced Science. https://doi.org/10.1002/advs.202202737
Vancouver
Yang T, Huang W, Ma T, Yin X, Zhang J, Huo M, et al. The PRMT6/PARP1/CRL4B Complex Regulates the Circadian Clock and Promotes Breast Tumorigenesis. Advanced Science. 2023. doi:10.1002/advs.202202737
BibTeX
@article{Yang2023,
author = {Yang, Tianshu and Huang, Wei and Ma, Tianyu and Yin, Xin and Zhang, Jingyao and Huo, Miaomiao and Hu, Ting and Gao, Tianyang and Liu, Wei and Zhang, Die and Yu, Hefen and Teng, Xu and Zhang, Min and Qin, Hao and Yang, Yunkai and Yuan, Baowen and Wang, Yan},
title = {The PRMT6/PARP1/CRL4B Complex Regulates the Circadian Clock and Promotes Breast Tumorigenesis},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202202737}
}
EUVIMED